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Abstract
SPARC, a matricellular protein with tumor suppressor properties in certain human cancers, was initially identified in a
genome-wide analysis of differentially expressed genes in chemotherapy resistance. Its exciting new role as a potential
chemosensitizer arises from its ability to augment the apoptotic cascade, although the exact mechanisms are unclear. This
study further examines the mechanism by which SPARC may be promoting apoptosis and identifies a smaller peptide
analogue with greater chemosensitizing and tumor-regressing properties than the native protein. We examined the
possibility that the apoptosis-enhancing activity of SPARC could reside within one of its three biological domains (N-
terminus (NT), the follistatin-like (FS), or extracellular (EC) domains), and identified the N-terminus as the region with its
chemosensitizing properties. These results were not only confirmed by studies utilizing stable cell lines overexpressing the
different domains of SPARC, but as well, with a synthetic 51-aa peptide spanning the NT-domain. It revealed that the NT-
domain induced a significantly greater reduction in cell viability than SPARC, and that it enhanced the apoptotic cascade via
its activation of caspase 8. Moreover, in chemotherapy resistant human colon, breast and pancreatic cancer cells, its
chemosensitizing properties also depended on its ability to dissociate Bcl2 from caspase 8. These observations translated to
clinically significant findings in that, in-vivo, mouse tumor xenografts overexpressing the NT-domain of SPARC had
significantly greater sensitivity to chemotherapy and tumor regression, even when compared to the highly-sensitive SPARC-
overexpressing tumors. Our results identified an interplay between the NT-domain, Bcl2 and caspase 8 that helps augment
apoptosis and as a consequence, a tumor’s response to therapy. This NT-domain of SPARC and its 51-aa peptide are highly
efficacious in modulating and enhancing apoptosis, thereby conferring greater chemosensitivity to resistant tumors. Our
findings provide additional insight into mechanisms involved in chemotherapy resistance and a potential novel therapeutic
that specifically targets this devastating phenomenon.
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Introduction
Many pathological conditions arise because of abnormal
regulation in cellular activities, such as apoptosis, that disrupt
the fine balance between cell survival and death. This dysregu-
lation can contribute to cancer initiation, progression, and even
influence a tumor’s response to chemotherapy. SPARC (secreted
protein and rich in cysteine), a matricellular protein found to be
underexpressed in certain cancers, has emerged as a multifunc-
tional protein capable of inhibiting the growth of neuroblastomas
[1], leukemia [2], pancreatic [3], colorectal [4] and ovarian
cancers [5]. Its pro-apoptotic activity in ovarian, pancreatic, lung
and colorectal cancers (CRC) [4,6,7], is also thought to enhance
chemotherapeutic response and reverse drug resistance [4,8].
Recent studies revealed that the recruitment and propagation of
the apoptotic cascade involved the interaction between the N-
terminus of caspase 8 and SPARC [8]. In this study, the
mechanisms involved in SPARC-mediated apoptosis are further
examined, with a specific focus on identifying a region within
SPARC that may be responsible for promoting apoptosis. This is
based on reports that the three structural domains of SPARC
contribute to this protein’s multi-functional yet distinct biological
properties (Fig. 1A): (1) N-terminus (NT), (2) follistatin-like (FS),
and (3) the extracellular C-terminus (EC) domains [9,10]. For
example, the N-terminus contributes to its cell spreading
properties [11], the follistatin-like domain contains cysteine-rich
residues, and has been shown to inhibit endolethial cell migration
[12,13], while the C-terminus contains the extracellular Ca
2+-
binding module [14] and may have anti-angiogenic properties
[11,13,15].
Our current study demonstrates that the pro-apoptotic activity
of SPARC is confined to a specific region of the protein, and that a
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26390Figure 1. Over-expression of the N-terminus domain of SPARC diminished cell viability and induced apoptosis in colorectal cancer
cell lines. A) The biological domains of SPARC (SP) and sites of mutations introduced within the N-terminus (SP-N), follistatin-like (SP-F), and
extracellular (SP-C) domains are represented. B-D) The effect on cell viability following over-expression of SPARC domains were assessed by transient
transfection of sensitive (B) and (C) CPT resistant MIP101 cells (MIP/CPT) with plasmid constructs for SP, SP-N, SP-F, SP-C, and empty vector (ZEO) for
48 h, followed by no treatment (gray bars) or treatment (white or red bars) with 100 mM CPT-11, for an additional 24 h. Cell viability was assessed by
WST assay. Transfection with the empty vector (ZEO) served as control for all experiments; ‘‘No txfn’’=untransfected cells. D) Transfection of
chemoresistant MIP/5FU cells with different mutations introduced into SP-N (SP-N mut 1 or SP-N mut2) no longer diminished the survival of cells
exposed to 1000 mM 5-FU for 24 hrs. E) Cell lines stably transfected with and overexpressing SPARC (MIP/SP), SP-N (MIP/SP-N), SP-F (MIP/SP-F), SP-C
(MIP/SP-C), and empty-vector (MIP/ZEO) were treated with 5 mM 5-FU for 24 h. (*)=statistically different (p,0.05) from respective untreated control
(B–E) F) Stable MIP101 cells overexpressing SPARC, the different SPARC domains or empty-vector control were assessed for apoptosis by M30
staining: i) Comparison of % M30 positive cells in different cell lines after exposure to 5 mM 5-FU for 24 h, ii) representative images from M30 staining
in cells after 5-FU treatment. Results represent mean 6 s.e. (n=3–4 independent studies).
doi:10.1371/journal.pone.0026390.g001
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capable of conferring greater apoptosis and tumor regression in
vivo. In addition, while we previously demonstrated an interaction
between SPARC and caspase 8 in potentiating the apoptotic
cascade [8], this study invokes Bcl2, an anti-apoptotic member of
the intrinsic/mitochondrial pathway of apoptosis, as an important
component in this interaction with caspase 8 and SPARC. This
network of interactions affects the apoptotic cascade which then
influences drug sensitivity, therapy response and reversal of drug
resistance.
Results
Effect of different SPARC domains on apoptosis
We previously showed that exposure to high levels of SPARC
enhances apoptosis and significantly reduces cell viability in CRC
cells that have become resistant to chemotherapy [4,8]. Although a
number of biological activities (such as inhibition of angiogenesis
and proliferation) have already been ascribed to smaller
proteolytic cleavage products of SPARC [10], it is not known if
any of them also induce apoptosis similar to the native protein.
Therefore, in order to investigate this possibility, sensitive and
resistant CRC MIP101 cells were transiently transfected with
vectors containing only the N-terminus (SP-N), the follistatin-like
(SP-F), or the C-terminus (SP-C) domains of SPARC, or mutant
domains (SP-Nmut1, SP-Nmut2, SP-Fmut1, SP-Fmut2) (Fig. 1A).
In the chemotherapy naı ¨ve (MIP101) and resistant cells (to CPT-
11, MIP/CPT; or to 5-FU, MIP/5FU) examined, transient over-
expression of SP-N reduced cell viability (Fig. 1B–D) in response to
chemotherapy. In sensitive cells, such as MIP101, this represented
an additional decrease in viability of 37.1863.65% (p,0.005)
following transfection with SP-N (Fig. 1B), in comparison to 5-FU-
treated ZEO (empty vector)-transfected cells. Even more signifi-
cant is the observation that SP-N also decreased cell viability in the
chemo-resistant cells examined (Fig. 1C, D).
Based on these initial results suggesting that a recombinant
protein containing only the N-terminus domain of SPARC was
capable of diminishing cell viability in not only sensitive CRC
cells, but also in their chemo-resistant counterparts, we decided to
validate this observation by mutating the N-terminus domain, and
found that the mutant forms no longer promoted a chemosensitiz-
ing effect. In resistant MIP/5FU cells, transient over-expression of
two different mutants of SP-N (SP-Nmut1, SP-Nmut2) failed to
increase their sensitivity to 5-FU (Fig. 1D), while over-expression
of wild-type SP-N was able to decrease cell viability by 24.560.8%
(p,0.005) in response to 5-FU.
This negative effect of the N-terminus domain of SPARC on
cell viability led us to further evaluate them using stable clones of
MIP101 cells over-expressing the N-terminus (MIP/SP-N), the
follistatin-like (MIP/SP-F), or the extracellular (MIP/SP-C)
domains. MIP/SP and MIP/SP-N cells showed the greatest
decrease in cell viability and proliferation after 5-FU treatment,
suggesting enhanced chemosensitivity in comparison to control
MIP/ZEO cells (Fig. 1E). This reduction in cell viability resulting
from overexpression of the N-terminus domain of SPARC was
associated with a 20-fold increase in the percentage of MIP/SP-N
cells undergoing apoptosis in response to 5-FU (Fig. 1F). A similar
but less dramatic response is seen with MIP/SP cells (Fig. 1F),
while no significant increase in apoptosis were observed in MIP/
SP-F or MIP/SP-C following exposure to 5-FU.
N-terminus domain of SPARC and apoptosis
We previously reported that SPARC-mediated apoptosis
involved the activation of the extrinsic pathway, via caspase 8
[8]. Given the above results, the possibility that the N-terminus
domain of SPARC may engage in a similar mechanism to
enhance apoptosis was investigated. Following exposure to 5-
FU, caspase 8 activity (based on its cleaved product, 43 kDa)
was mainly observed in MIP/SP-N cells (Fig. 2A). There was
also higher expression of cleaved-BID and earlier activation of
caspase 3 in MIP/SP-N cells (by 8 hrs after exposure to 5-FU),
suggesting a similar involvement of the extrinsic pathway in cells
over-expressing the N-terminus domain. To further validate the
involvement of caspase 8 and Bid in the N-terminus-mediated
apoptotic events, siRNA knock-down studies were undertaken
which revealed that the absence of caspase 8 eliminated the
apoptotic response following treatment with chemotherapy in
MIP/SP and MIP/SP-N cells, as measured by cell viability
assays (Fig. 2B) and caspase 3/7 activity (Fig. 2C). Similarly, in
the absence of Bid following siRNA knock-down, MIP/SP and
MIP/SP-N cells also demonstrated a diminished caspase 3/7
response to chemotherapy (Fig. 2D). Interestingly, while
intrinsically high SPARC-expressing HCT116 cells were also
no longer responsive to chemotherapy following caspase 8 and
Bid gene-silencing, cells overexpressing the FS- and EC-domains
of SPARC were unaffected by caspase 8 or Bid knock-down
(Fig. 2B–D).
Tumor xenografts overexpressing the N-terminus
domain of SPARC are more chemosensitive
The results of the in-vitro studies indicate that the N-terminus
domain of SPARC alone is capable of enhancing chemosensitivity.
This, together with previous in-vivo studies demonstrating greater
tumor regression of xenografts of MIP/SP cells to chemotherapy
[4] led us to examine if tumor xenografts overexpressing the N-
terminus domain of SPARC also had a heightened sensitivity to
chemotherapy.
Indeed, in-vivo, MIP/SP-N cells were also more sensitive to
chemotherapy than xenografts of MIP/ZEO control cells:
xenografts of tumors over-expressing either the N-terminus
domain or SPARC were the most responsive to 5-FU treatment,
as tumors remained ,400 mm
3 after 41 days of treatment,
while saline-treated animals harbored tumors greater than
1144.16181.3 mm
3 (Fig. 3A,B). Tumor xenografts of cells
overexpressing the other domains of SPARC did not differ in
size between the treatment and control groups. There was also a
significantly longer tumor doubling times for MIP/SP and MIP/
SP-N saline-treated xenografts, in comparison to MIP/ZEO
xenografts (p,0.005; Fig. 3C). Xenografts of MIP/SP-C had a
similar tumor doubling time as MIP/ZEO (p=0.07), while MIP/
SP-F had a faster growth rate (p,0.005).
The extent of tumor regression correlated with a greater
percentage of cells undergoing apoptosis in xenografts of MIP/SP
(22.262.4% vs 4.263.1% in control, p=0.01) and MIP/SP-N
(31.363.2% vs 4.360.9% in control, p,0.005) cells following
treatment with 5-FU in comparison to their saline-treated
counterparts (Fig. 3D, E). Caspase 3 (cleaved) expression was also
highest in tumors of MIP/SP-N and MIP/SP cells (Figure S1). No
differences were detected in xenografts of the other cell lines,
despite 5-FU treatment. Angiogenesis also appeared to be affected,
as xenografts of MIP/SP and MIP/SP-N cells showed significantly
fewer CD31+ staining than xenografts of MIP/ZEO, MIP/SP-F
or MIP/SP-C (p,0.05, Fig. 3F). These findings demonstrate that
a fragment of SPARC containing only its N-terminus domain has
similar biological activities as the full-length protein in relation to
its ability to promote apoptosis while inhibiting angiogenesis
[4,16].
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prevents its interaction with Bcl2
The ability ofSPARC topromote greater apoptosis in-vitroand in-
vivo following exposure to cytotoxic agents [4] results, in part, from its
interaction with caspase 8 leading to the activation of the extrinsic
pathway of apoptosis [8]. A similar interaction was detected with the
N-terminus domain of SPARC, but not the FS- or EC-domains,
following co-immunoprecipitation studies using antibodies against
caspase 8 and His6 (to detect fusion proteins of the NT, FS or EC-
domains) (Fig. 4A). To further validate this observation, cells
transiently overexpressing the wild-type NT-domain effectively co-
immunoprecipitated caspase 8, while this interaction was absent with
mutant proteins SP-Nmut1, and SP-Nmut2 (Fig. 4B).
Our finding of an interaction between caspase 8 and SPARC,
and previous reports of an interaction between caspase 8 and Bcl2
in neuroblastomas [17], led us to examine if such an interaction
also occurs in cancer cells and whether it can be influenced by
SPARC to facilitate apoptosis in response to chemotherapy. Our
findings were interesting in that an interaction between caspase 8
and Bcl2 was detected in chemoresistant MIP/5FU cells, but not
in sensitive MIP/ZEO and MIP/SP cells (Fig. 5A). This pattern of
interaction was replicated in other chemotherapy-resistant cancer
cells (Fig. 5B): CRC RKO/5FU, RKO/CPT, RKO/CIS;
pancreatic MiaPaca/CPT; and breast cancer MCF-7/CIS. Even
more exciting is the observation that when RKO/5FU cells were
incubated with recombinant SPARC (rSPARC), the interaction
Figure 3. Xenografts overexpressing SP-N have greater tumor regression and apoptosis in response to 5-FU. A,B) Comparison of
tumor size in xenografts from MIP/SP-N, MIP/SP-F, MIP/SP-C, and MIP/ZEO cells with or without treatment with 5-FU; ‘‘+’’=5-FU-treatment;
‘‘2’’=saline-treatment, (n=14/group; mean 6 s.e). C) Tumor doubling times of xenografts following 5-FU treatment. (D) Percentage of apoptotic
cells detected by TUNEL staining [representative images in (E)]. (F) number of CD31-positive stained blood vessels in the tumor xenografts of (&)
saline or (%) 5-FU-treated animals. Student’s t-test * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0026390.g003
Figure 2. N-terminus domain of SPARC activates caspase 8 in response to treatment with 5-FU. A) Changes in the expression of proteins
involved in the apoptotic pathway following incubation with 5-FU at different time points in MIP101 cells stably overexpressing SPARC domains by
immunoblotting. B–D) The contribution of caspase 8 or Bid in inducing SP-N-associated apoptosis were compared with various cell lines after
transient transfection with caspase 8 and Bid siRNA (or scramble control) for 48 h, followed by no treatment (grey bars) or incubation with 5-FU
(white or orange bars) for 24 h. Cell viability after caspase 8 siRNA transfection was assessed by WST assay (B), while apoptosis after caspase 8 (C)o r
Bid (D) siRNA transfection was assessed by caspase 3/7 assay. Results represent mean 6 s.e. (n=3–4 independent studies). *p,0.05, Student’s t-test,
in comparison to untreated controls.
doi:10.1371/journal.pone.0026390.g002
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Fig. 5B).
Based on these observations, we proceeded to determine the
region of caspase 8 that interacts with Bcl2, by incubating
chemotherapy-resistant cells with antibodies targeting either the
N- or C-terminus of caspase 8, and observed that the interaction
could only be abolished when antibodies blocked the N-terminus
of caspase 8 (Fig. 5C, Figure S2C). In addition, this caspase 8-Bcl2
interaction appeared to localize to the membrane fraction, and in
line with previous results, was eliminated following exposure to
rSPARC (Fig. 5D). However, co-incubation with rSPARC in the
presence of anti-SPARC antibodies again restored this caspase 8-
Bcl2 interaction (Fig. 5D).
These observations indicate that interactions involving Bcl2,
caspase 8 and SPARC exist in cancer cells. In order to assess the
significance of the interaction, the expression of Bcl2 was
modulated by decreasing its expression in chemoresistant MIP/
5FU cells. Only following a reduction in Bcl2 expression by siRNA
transfection was there a decrease in cell viability in response to 5-
FU (p=0.04) or SPARC alone (p=0.003), and these results were
even more significant when the treatment included a combination
of 5-FU with escalating concentrations of SPARC (Fig. 5E). These
results support the biological importance of a Bcl2-caspase 8-
SPARC interaction in modulating chemosensitivity.
A synthetic peptide of the N-terminus of SPARC
enhances apoptosis by inhibiting the interaction
between caspase 8 and Bcl2
In order to confirm that the N-terminus of SPARC did indeed
confer greater chemosensitivity by augmenting apoptosis by
interfering with the interaction between caspase 8 and Bcl2, we
generated a synthetic peptide of the N-terminus of SPARC
(peptide-NT), tagged with a TAT peptide (YGRKKRRQRRR) to
facilitate its intracellular uptake. Caspase 3/7 assays confirmed
,40–60% increase in apoptotic activity in not only sensitive MIP
and RKO CRC cells, but as well the resistant MIP/5FU and
RKO/5FU cells following incubation with peptide-NT and 5 mM
5-FU for 24 hrs (Fig. 6A). Also in line with previous observations:
(1) cell viability also diminished significantly following exposure to
this novel combination (Fig. 6B), and (2) immunoprecipitation
studies revealed peptide-NT’s ability to disrupt the interaction
between caspase 8 and Bcl2 (Fig. 6C). These exciting results not
only support our findings that the apoptosis-conferring region of
Figure 4. The site of interaction between SPARC and caspase 8 is at the N-terminus of SPARC. Co-localization of the N-terminus of SPARC
with caspase 8 was determined by co-immunoprecipitation (IP) studies using whole protein extracts. A) Only the recombinant N-terminus containing
His-tagged fusion protein from MIP/SP-N cells co-IP with caspase 8 in a reciprocal fashion. B) Mutations in the N-terminus domain of SPARC (SP-
Nmut1, SP-Nmut2) abolishes this interaction with caspase 8, and only the wild-type SP-N interacted with caspase 8. As additional controls, neither the
wild type nor the mutant FS domain (SP-Fmut1, SP-Fmut2) interacted with caspase 8.
doi:10.1371/journal.pone.0026390.g004
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peptide of this region is capable of chemosensitizing therapy-
refractory cells.
Mutations in the DED-domains of caspase 8 prevent
interactions with Bcl2 and SPARC
To identify the specific site within caspase 8 that interacts with
Bcl2 or SPARC, mutations were introduced in three different
regions of the N-terminus of caspase 8: the DEDI-domain
(DEDIm), the putative binding region (PBm), and DEDII-domain
(DEDIIm). Co-immunoprecipitation studies revealed that tran-
sient overexpression of DEDIm and DEDIIm caspase 8 mutants
interfered with the ability of Bcl2 to interact with caspase 8 in
MIP/5FU and MiaPaca/CPT cells (Fig. 7A). In MIP/SP cells,
overexpression of DEDIm-caspase 8 eliminated the interaction
between SPARC-caspase 8, while mutations in the PB or DEDII-
domains still allowed caspase 8 to interact with SPARC (Fig. 7B).
These results suggest that the DEDI-domain of caspase 8 is the site
of interaction with SPARC and Bcl2. Interestingly, we also noted
that over-expression of caspase 8-mutants abolished the reduction
in cell viability and increase in apopotosis that is normally
conferred by caspase 8 in the presence of SPARC and 5-FU, in
resistant cells (Fig. 7D–F). Similar observations were noted with
chemosensitive MIP/SP and MIP/SP-N cells (Fig. 8A–C). Also,
MIP/SP-Nmut cells failed to respond to 5-FU following
transfection with either wild-type or mutant caspase 8
(Fig. 8D,E), thus supporting the N-terminus of SPARC as the
site of interaction with caspase 8.
The results reported in this study reveal how an interplay
between SPARC, caspase 8 and Bcl2 may modulate apoptosis in
response to cytotoxic agents. In addition, higher Bcl2 levels in
human CRC (Fig. 8F) suggest that the ability of SPARC to
interfere with Bcl2’s interaction with caspase 8 may be clinically
relevant and can be targeted as a potential therapeutic.
Figure 5. SPARC and Bcl2 both interact with caspase 8 with opposing effects. (A) In resistant MIP/5FU cells, caspase 8 interacts with Bcl2
and this is also observed in other resistant colorectal (RKO/5FU, RKO/CPT, RKO/CIS), pancreatic (MiaPaca/CPT) and breast cancer (MCF/CIS) cell lines
(B). The Bcl2-caspase 8 interaction can be eliminated following exposure to rSPARC (100 ng/mL) (denoted as ‘‘*’’). C) The interaction between Bcl2-
caspase 8 occurs at the N-terminus of caspase 8 as cells incubated with antibodies blocking the N-terminus of caspase 8 (N-term, 1.5–3 mg) prevented
this Bcl2-caspase 8 interaction. D) Bcl2-caspase 8 interaction is abolished after exposure to 100 ng/mL rSPARC in resistant MIP/5FU and MiaPaca/CPT
cells. (E) Chemoresistant MIP/5FU cells transfected with Bcl2 siRNA to reduce Bcl2 expression are now responsive to 1000 mM 5-FU (+), especially in
combination with incremental concentrations of rSPARC (20–100 ng/ml). Results represent mean 6 s.e. (n=3 independent studies). Student’s t-test,
statistically significant when p,0.05.
doi:10.1371/journal.pone.0026390.g005
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Apoptosis occurs as a result of a series of well coordinated events
that classically involve either activation of the extrinsic or intrinsic
pathways and members of the Bcl2 protein family. We and others
have previously shown that high levels of SPARC, a matricellular
protein known to influence cell growth and apoptosis, to be
associated with increased apoptosis in ovarian, pancreatic and
CRCs [4,6,7], and that its exogenous exposure in-vivo promotes
greater tumor regression in CRCs that had become refractory to
conventional chemotherapies [4]. Recently, we identified a
potential mechanism that allows SPARC to augment the apoptotic
cascade, enhancing the effect of cytotoxic agents used in the
treatment of malignancies [8]: SPARC promotes the activation of
the extrinsic pathway of apoptosis by interacting with the N-
terminus of caspase 8, with subsequent involvement of the intrinsic
pathway, via Bid, to enhance apoptosis [8]. As an extension to
these earlier observations, the current study demonstrates that in
cancer cells that have become resistant to chemotherapy, the N-
terminus of caspase 8 interacts instead with Bcl2 to restrict
apoptosis. However, this inhibitory effect on apoptosis is reversible
in the presence of higher levels of SPARC, either following
exogenous exposure to this protein or its forced endogenous over-
expression. Importantly, we not only identify the site interacting
with caspase 8 as the N-terminus domain of SPARC, but that a
synthetic peptide of this region (51aa in length) is responsible for
conferring SPARC’s apoptotic activity. In fact, our results
demonstrate that tumor xenografts of cells over-expressing only
the N-terminus domain of SPARC, and not others, experienced
the most dramatic tumor regression in response to chemotherapy.
SPARC is expressed in many different cell types [18] and plays
a complex role in tumorigenesis. While some studies report a
positive association between high SPARC and more aggressive
tumors [19,20], several studies, including our own, support the
view that it functions in part as a tumor suppressor in
neuroblastomas, leukemias, colorectal, ovarian, pancreatic, lung,
and breast cancers [3,4,6,7,21,22]. These divergent actions of
SPARC are puzzling, but may be explained by differences in the
biological activities of the various proteolytic products of SPARC.
Specifically, previous studies have demonstrated that SPARC
undergoes proteolysis by a variety of proteases, such as
metalloproteinases (MMPs), elastases, cathepsins, and serine
proteases [23]. These degradation products have differing
biological activities [10]: for example, a small peptide containing
only 20 amino acids (aa 21–40) of the N-terminus domain of
SPARC had previously been shown to inhibit endothelial cell
spreading and bFGF-induced cell migration [24]; and the native
SPARC protein is also known for its ability to inhibit angiogenesis
[10], yet release of a proteolytic product containing the Cu
2+
binding sequence KGHK (lysine-glycine-histidine-lysine) opposes
the activity of the full-length protein by instead, stimulating
angiogenesis in-vitro and in-vivo [25,26]. Therefore, differences in
tumor-specific protease expression may account for the differences
in SPARC’s biological behavior in tumorigenesis and different
cancers. This also helps explain our findings that the effect of the
recombinant peptide of SPARC’s N-terminus domain on tumor
Figure 6. Augmentation of apoptosis by peptide-NT. Sensitive MIP101 or RKO and 5-FU resistant MIP/5FU and RKO/5FU cells were incubated
with peptide-NT 100 ng/ml +/2 5-FU 5 mM for 24 hrs and assayed for (A) caspase 3/7 levels, or (B) cell viability by MTT assays. (C) Immunoblots
showing the ability of peptide-NT to interfere with the interaction between caspase 8 and Bcl2: MIP/5FU cells were incubated with peptide-NT or
scramble control peptides 1 or 2 for 24 hrs; cell pellets were collected 24 hrs later for co-immunoprecipitation studies.
doi:10.1371/journal.pone.0026390.g006
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e26390Figure 7. The DEDI-domain of caspase 8 is critical for its interaction with Bcl2. Vectors containing mutations in specific domains (DEDI,
putative binding(PB), DEDII) of caspase 8 were transiently transfected into (A) MIP/5FU, MiaPaca/CPT or (B) MIP/SP cells, to determine the ability of
the mutant proteins to co-IP with Bcl2 or SPARC. C) Basal levels of caspase 8 gene expression between various cancer cell lines. D–F) The effect of
SPARC on cell viability (D, E) or apoptosis (F) in cells overexpressing mutant forms of caspase 8 was assessed. Cells were transiently transfected with
wild-type caspase 8 (Csp8), mutants (DEDIm, PBm, and DEDIIm), or empty-vector (EV, control) for 48 h, followed by exposure to 100 ng/mL rSPARC
for 48 h, and treated with 0 (&) or 500 mM( %)5-FU for an additional 24 h. D–E) In resistant cells, exposure to rSPARC and 5-FU resulted in decreased
cell viability following transfection with EV-control: MIP/5FU: 90.1462.80 (SPARC) vs. 69.8964.64% (SPARC+5-FU) (p,0.005); MiaPaca/CPT:
108.7766.85 (SPARC) vs. 73.9864.46% (SPARC+5-FU) (p,0.005). Over-expression of wild-type caspase 8 in resistant cells further decreased cell
viability following exposure to rSPARC and 5-FU, in comparison to EV-controls: MIP/5FU: 69.8964.64 (SPARC + 5-FU) vs. 59.2163.66% (SPARC + 5-FU
+ caspase 8) (p=0.03); MiaPaca/CPT: 73.9864.46 (SPARC + 5-FU) vs. 46.7862.01% (SPARC + 5-FU + caspase 8) (p,0.005). However, over-expression of
mutant forms of caspase 8 abolished the reduction in cell viability seen in the presence of rSPARC. Results represent mean 6 s.e. (n=3 independent
studies). *p,0.05, Student’s t-test.
doi:10.1371/journal.pone.0026390.g007
Figure 8. Interaction between the N-terminus of both caspase 8 and SPARC are required to reduce cell viability and enhance
apoptosis. A–B) Cell viability further decreased in MIP/SP and MIP/SP-N after transfection with wild-type caspase 8 and 5-FU treatment, relative to
empty vector (EV, control): MIP/SP: 77.263.8 (EV) vs. 59.161.5% (caspase 8) (p,0.005); MIP/SP-N: 68.864.8 (EV) vs. 50.663.6% (caspase 8) (p=0.04).
Transfection with any of the caspase 8 mutants eliminated their response to 5-FU, not only in terms of cell viability, but apoptosis (C). In cells
overexpressing mutant SP-N (MIP/SP-Nmut1), transfection with caspase 8 was incapable of decreasing cell viability (D) or increasing apoptosis (E).
Results represent mean 6 s.e. (n=3 independent studies). *p,0.05, Student’s t-test. F) Bcl2 expression of clinical specimens of human CRCs obtained
from the same individual following primary tumor resection (chemotherapy-naı ¨ve) and disease recurrence post-chemotherapy (chemotherapy-
resistant) (paraffin-embedded 6 mM sections).
doi:10.1371/journal.pone.0026390.g008
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apoptosis in response to 5-FU, it also reduced the rate of tumor
growth by , 40% in comparison to SPARC-over-expressing
tumors. Our findings indicate that while SPARC’s N-terminus
domain inhibits tumor growth, the follistatin-like (FS-) domain
alone may have growth-promoting properties, as xenografts
overexpressing recombinant proteins of this fragment had
significantly shorter doubling times than control xenografts. These
tumors were also unresponsive to 5-FU treatment. Taken together,
these observations suggest that the efficacy of the native SPARC
protein on tumor regression may be blunted when its proteolysis
results in the release of different fragments with opposing
biological effects. These observations again reflect SPARC’s
intricate biology, as potential proteolytic products may have
opposing effects on tumor growth, progression and response to
therapy. This is an area that requires further investigations, in
order to allow a better understanding of SPARC’s effect in
different types of cancers.
Based on the results of the current study, another dimension
has been added to the multifaceted biological behavior of
SPARC, by demonstrating the pro-apoptotic activity of the N-
terminus domain of SPARC. In addition, we further confirm the
involvement of Bid in SPARC-mediated apoptosis as cells
overexpressing only the N-terminus of SPARC (MIP/SP-N) are
capable of activating Bid, and this effect was easily abolished
with Bid-siRNA in MIP/SP-N cells only. More importantly, we
show that the ability of either SPARC or its smaller N-terminus
domain to promote apoptosis results from their interference in
Bcl2’s interaction with caspase 8, thereby leading to the
activation of the extrinsic pathway (Fig. 9). Our assessment of
a potential triad involving SPARC-caspase 8-Bcl2 in regulating
apoptosis was based on earlier observations that Bcl2 binds to
caspase 8 to inhibit caspase 8-mediated apoptosis in Fas-
resistant neuroblastomas [17]; reports of SPARC’s ability to
promote apoptosis by decreasing the ratio of Bcl2 and BAX in
autosomal dominant polycystic kidney cells [27], together with
o u rr e c e n to b s e r v a t i o n st h a td e c r e a s i n gS P A R Ce x p r e s s i o nb y
siRNA diminishes chemosensitivity [28] and that this effect is
based on SPARC’s ability to interact with caspase 8 to promote
apoptosis [8]. Bcl2 has long been associated with drug resistance
since its discovery as a proto-oncogene in non-Hodgkin’s B-cell
lymphomas [29], and over the years, it has been extensively
studied as a potential target for cancer therapy [30]. Recently,
the differential compartmentalization of Bcl2 and NRAS has
been reported to influence disease states, such as myelodysplas-
tic syndromes and acute myeloid leukemia [31]. In their mouse
model, the physical interaction of Bcl2 and mutant NRAS
affected the apoptotic machinery. These novel interactions
between Bcl2 and other proteins, as demonstrated by us and
others, highlight the complex mechanisms utilized by cancer
cells to evade cell death, leading to disease progression and drug
resistance.
In this study, we demonstrate that Bcl2 and caspase 8 interact in
cancer cells that have become refractory to therapy, thus providing
another mechanism by which Bcl2 promotes survival and drug
resistance. In addition, our in-vitro and in-vivo results reveal that
the N-terminus domain of SPARC, and its synthetic peptide, are
highly efficacious in modulating and enhancing apoptosis, in part,
through its ability to dissociate the interaction between Bcl2 and
caspase 8. These exciting findings point to the possibility that this
smaller N-terminus peptide, based on its ability to interfere with
the Bcl2-caspase 8 interaction, can be exploited as a potential
therapeutic in disease states, such as cancer, where augmentation
of the apoptotic cascade is clinically beneficial.
Materials and Methods
Cell Lines, Reagents
Colorectal (MIP101, HCT 116, RKO), pancreatic (MiaPaCa)
and breast (MCF-7) cancer cells (sensitive and resistant) were
maintained in DMEM media as previously described [4].
HCT116, RKO, MiaPaCa and MCF-7 were obtained from
ATCC. MIP101 cells were kind gifts from Dr. Lan Bo Chen [32].
Also, please refer to Table S1 for a list of abbreviations. For
resistant cells, media were also supplemented as follows: MIP/
5FU, 500 mM 5-FU; MIP/CPT, 10 mM CPT-11; HCT116/5FU,
10 mM 5-FU; RKO/5FU, 25 mM 5-FU; RKO/CPT, 18 mM
CPT-11; cisplatin (CIS) (RKO/CIS), 30 mM CIS; MiaPaca/CPT,
100 mM CPT-11; MCF7/CIS, 30 mM CIS. MIP101 transfected
with empty vector (MIP/ZEO) or stably transfected with SPARC
(MIP/SP) underwent selection with Zeocin (Invitrogen).
Mammalian expression vectors containing the N-terminus (SP-
N), follistatin-like (SP-F), and extracellular (SP-C) domains of
SPARC were kind gifts from Dr. W. Schiemann (National Jewish
Medical and Research Centre; Denver, CO). The recombinant
proteins were myc/His6–tagged [33]. MIP101 cells stably
transfected with SP-N (MIP/SP-N), SP-F (MIP/SP-F), or SP-C
(MIP/SP-C) were also generated and selected for hygromycin-
resistance. Overexpression of these recombinant proteins in cells
were confirmed by ELISA (Figure S3). Of note, previous studies
utilizing tagged-SPARC (or related peptides) have demonstrated
similar biological activity as the native, un-tagged proteins [33,34],
therefore, myc or His6–tagged proteins were used in these studies.
Recombinant human SPARC (rSPARC), were generously
provided by Dr. Desai (Abraxis BioScience Inc., USA). Human
peptide of the N-terminus domain of SPARC (Peptide sequence:
APQQEALPDETEVVEETVAEVTEVSVGANPVQVEVGEFD-
DGAEETEEEVVA) was synthesized by AnaSpec (USA) with a
TAT sequence (YGRKKRRQRRR) added to its amino-terminus,
to facilitate its intracellular entry.
Site-directed Mutagenesis
SPARC (SP), SP-N, SP-F, and caspase 8 containing plasmids
were used for site-directed mutagenesis, using GeneTailor Site-
Directed Mutagenesis System (Invitrogen) as per manufacturer’s
protocol. Mutant constructs were verified by DNA sequencing.
Please refer to Table S2 for a list of primers used.
Transfection studies
Plasmids. In order to assess if the smaller peptides
representing the different domains of SPARC had an effect on
cell viability, cells were transiently transfected with constructs
containing: SPARC (SP), SPARC’s N-terminus domain (SP-N),
mutant FS-domain (SP-F), EC domain (SP-C); mutant N-terminus
domain (SP-Nmut1, SP-Nmut2), FS-domain (SP-Fmut1, SP-
Fmut2); wild-type caspase 8 or mutant DEDI-domain (DEDIm),
putative-binding-domain (PBm), DEDII-domain (DEDIIm); or
empty-vector control (ZEO) for 48-hours. Depending on the study,
cells were then exposed to 100 ng/mL SPARC, and/or 5–
1000 mM 5-FU (MIP101-related cells; with the higher
concentrations of 5-FU used in the resistant MIP/5FU cells as
their IC50 was .18-fold higher than sensitive MIP101 cells), 50–
100 mM CPT-11 (MIP101 related cells), 18–36 mM CPT-11
(RKO-related cells), 100–200 mM CPT-11 (MiaPaca-related cells),
or 60 mM CIS (MCF7-related cells) for 24–48-hours. Stable cell
lines overexpressing the different SPARC domains were also
generated and subjected to similar treatment protocols. Cell
viability and proliferation were assessed by WST reagent (Roche)
at 450 nM [8] at the completion of the study.
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using 40 nM caspase 8 siRNA (Stealth RNAi, Invitrogen) was
assessed as previously described, using similar conditions that
resulted in a 14-fold reduction in gene expression [8]. Transfection
with siRNA was performed for 48-hrs before additional treatments
or assays were performed. The conditions for Bid siRNA
transfection were tested using 20–40 nM siRNA (Stealth RNAi.
Invitrogen) and the degree of knock-down determined 48 and
72 hrs later (Figure S2A). The most effective knock-down was
obtained following transfection with 40 nM of Bid siRNA for
either 48 or 72 hrs. All subsequent experiments were performed
using 40 nM siRNA for 48 hrs. For Bcl2, conditions were
optimized using 40–80 nM siRNA (Stealth RNAi, Invitrogen)
and 4.5 uL of HiperFect-Transfection Reagent (Qiagen) for 48–
72 hrs. At 72 hr following transfection with 40 and 80 nM of
siRNA, a 40% and 60% reduction in Bcl2 expression was
achieved, respectively (Figure S2B). In subsequent experiments,
80 nM Bcl2 siRNA for 72 hrs were used. As control, scramble
oligonucleotide sequences were used. For RT-PCR, RNA was
isolated with Trizol (Invitrogen), and 1 mg of total RNA was used
to generate cDNA (Superscript III, Invitrogen). Specific primers
used for PCR include: Bcl2 (forward)59-atctgggccacaagtgaagt-39,
(reverse)59-cttctccccagcctccag-39; Bid (forward)59-aaaaccacatgg-
cacagaga-39, (reverse)59-agagggaaccactttgctga-39; and under the
following PCR conditions: 94uC62 min; 35 cycles of 94uC630 s,
58uC620 s, 72uC630 s; 72uC630 s, PCR products were
separated on a 1.5% agarose gel electrophoresis, and levels of
expression quantified using ImageJ.
ELISA for quantification of SPARC and related peptides
Stable cell lines (MIP/ZEO, MIP/SP, MIP/SP-N, MIP/SP-F
and MIP/SP-C) or transiently transfected cells were grown to 90%
confluence and proteins from whole cell lysates were isolated as
previously described [4]. Microwells were coated with anti-
SPARC antibody (1:5000) in coating buffer (0.1 M sodium
carbonate, pH 9.5) overnight at 4uC, washed 36 with PBS-T
(0.05% Tween-20), and blocked with 2%BSA in PBS for 1-hour at
RT. 5 mg of total protein was added to each well in triplicate,
incubated at 4uC for 4-hrs, and washed 36 with PBS-T. Wells
were then incubated with either anti-His or anti-myc (1:5000,
Sigma; all expression constructs express His6/myc-tagged fusion
proteins) antibodies for 2-hours at RT, washed 56 with PBS-T,
and incubated with appropriate secondary-HRP antibodies
(1:10 000) for 1-hour at RT. Wells were then washed 56 with
Figure 9. A model: SPARC-mediated apoptosis. A schematic of SPARC and Bcl2 interacting with caspase 8 to influence apoptosis. In this study,
we demonstrate that in an environment low in SPARC, Bcl2 interacts with caspase 8 to inhibit apoptosis. However, in the presence of SPARC or its N-
terminus, these proteins interact with caspase 8 to inhibit its interaction with Bcl2, leading to an augmentation of the apoptotic cascade.
doi:10.1371/journal.pone.0026390.g009
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each well for 15–30-minutes. Absorbance was read at 650 nM.
Results of the ELISA are provided in Figure S3.
Apoptosis
M30 Antibody staining. Cells were seeded and treated
48 hours later with 5 mM 5-FU for an additional 48 hours,
harvested and fixed onto glass slides by Cytospin, and stained with
M30 antibodies (M30 CytoDEATH monoclonal antibody,
ALEXIS Biochemicals, Switzerland) as per manufacturer’s
protocol.
Caspase- 3/7 assay. 20 mg of total protein isolated from cell
lysates were used in Caspase-Glo 3/7 Assay (Promega) as
previously described [35]. The relative luminescence units (RLU)
were measured using Viktor
2 1320 Multilabel-platform (Perkin
Elmer).
Immunoblot analysis
48 hours after plating, cells were incubated with 5 mM 5-FU,
and collected at 0–12 hours for immunoblotting as previously
described [4,36]. Immunodetection was performed using antibod-
ies against caspase 8 (1:1000, Santa Cruz Biotechnology, Inc) or
cleaved-caspase 8, BID, and caspase 3 (all 1:1000, Cell Signaling
Technologies) followed by incubation with the appropriate
secondary antibody. All immunoblots were also probed with
antibodies to b-actin (0.32 mg/mL, Abcam) as loading control.
Proteins were detected with SuperSignal West Dura (Pierce).
Subcellular Fractionation, Co-Immunoprecipitation
Total protein was isolated from cells grown to ,80%
confluence, then separated into nuclear, cytosolic, and membrane
fractions as previously described [8]. 250 mg of individual cellular
fractions were incubated with antibodies against His6 or myc
(1:100), caspase 8 (N-terminus, 1:100, Abcam), Bcl2 (1:100, Cell
Signaling Technologies) or a non-specific anti-mouse-IgG anti-
body as control (Cell Signaling Technologies), in PBS overnight
(4uC). Protein:Antibody mixture was then incubated with 30 mLo f
Protein A:Protein G beads (1:1,Sigma) for 4-hours (4uC), washed
with PBS, and eluted with 26 SDS-loading buffer, and used for
immunoblotting against caspase 8, His6, or Bcl2 [8].
Animal Studies
Tumor xenograft animal models were used to assess how
overexpression of the various fragments of SPARC could influence
tumor progression and response to chemotherapy in-vivo. Nude
mice were implanted with 1610
6 (MIP/ZEO, MIP/SP, MIP/SP-
N, MIP/SP-F, or MIP/SP-C) cells into the flanks of each animal.
Treatment with 5-FU using a 3-week cycle regimen (6 cycles),
commenced once the average tumor size reached 75–100 mm
3
[4]. Control animals received saline. All studies were approved by
the Animal Care Committee at the University of British
Columbia, Canada (protocol A06-1507). Doubling time was
averaged from all tumor measurements and calculated as: t1/2
=(t 2-t1)*ln(2)/ln(volume2/volume1). In order to minimize differ-
ences in tumor engraftment as a potential reason for influencing
the variability in cell doubling time, all xenografts were implanted
with the same number of cells and only mice with tumors ,75–
100 mm
3 in size by 2 weeks following implantation were used in
the in-vivo studies.
Immunohistochemistry. For caspase 8 (1:100), Bcl2 (1:100),
and SPARC (1:100, Hematological technologies) expression,
OCT-embedded tissues were sectioned and processed according
to established protocols [4,36]; counterstained with TO-PRO-3
iodide (Invitrogen). Confocal Zeiss-Nikon microscope was used for
image capture and Olympus BX61 microscope for light
microscopy.
CD31 staining. Tumors embedded in OCT-media were
sectioned and fixed in acetone for 10-minutes at 4uC, washed in
16PBS, blocked in 2% NCS for 20-minutes at RT, and incubated
in CD31 antibody (1:100, DAKO) overnight at 4uC. Sections were
counterstained with DAPI (Molecular probes). Zeiss-Axioplan2
fluorescence microscope was used for imaging. The number of
CD31-positive cells were counted and averaged from three
different fields (n=3 independent tumors).
Routine histology was also performed on paraffin-embedded
tissues (6 mM thick) [8] for hematoxyline and eosin (H&E) or
cleaved-caspase 3 staining (1:25 dilution). Leica MicroSystems
Bond-Max was used to stain tissue slides with cleaved-caspase 3
based on the manufacturer’s protocols with the following
modifications: Leica’s ER1 Solution (citrate based buffer) was
used for antigen retrieval (10-min6100uC), followed by a 10-min
peroxide block at RT. Cleaved-caspase 3 antibody was incubated
overnight at 4uC, then stained with hematoxylin. H&E images
were captured with a Zeiss Axioplan 2 microscope, while images of
caspase 3 stained slides were analyzed with a Leica DM600B
microsope and Surveyor (version 5.5.5.12).
Supporting Information
Figure S1 Histology of tumor xenografts. Tumor xeno-
grafts of MIP/ZEO, MIP/SP, MIP/SP-N, MIP/SP-F, and MIP/
SP-C subcutaneously implanted cells were paraffin-embedded and
processed and stained with Hematoxylin and Eosin (H&E), and
cleaved caspase 3.
(TIF)
Figure S2 siRNA optimization for Bid and Bcl2; and
interaction between Bcl2 and caspase 8 in various
resistant cells. A) Bid siRNA optimization: MIP101 cells were
transfected with 20–40 nM Bid siRNA (or scramble control). RNA
was isolated from cells harvested after 48–72 hrs of transfection
and Bid gene expression determined by RT-PCR. Optimal Bid
gene expression knock-down was achieved after transfection of
40 nM of siRNA for either 48–72 hrs; B) Bcl2 siRNA optimiza-
tion: MIP/5FU cells were transfected with 40–80 nM Bcl2 siRNA
(or scramble control) for 72 hrs. A 40% and 60% reduction in Bcl2
gene expression was noted following transfection with 40 nM and
80 nM respectively. The optimal condition used in subsequent
experiments included the transfection of cells with 80 nM of Bcl2
siRNA for 72 hrs; C) The interaction between Bcl2-caspase 8
occurs at the N-terminus of caspase 8 as cells incubated with
antibodies blocking caspase 8 (N-term, 1.5–3 mg) prevented this
Bcl2-caspase 8 interaction.
(TIF)
Figure S3 Levels of SPARC and related peptides in cells
used in this study. Cell lysates from stable transfectants (in-vitro
and in-vivo) or transiently transfected cells were isolated 120 hours
post-transfection and levels of SPARC and SPARC-related
peptide levels were assayed by ELISA. Results represent mean
6 s.e. (n=3 independent studies). Student’s t-test, * statistical
difference compared to control, where p,0.05.
(TIF)
Table S1 List of abbreviations.
(DOC)
Table S2 Site-directed mutagenesis primers.
(DOC)
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